Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment

针对癌症风险、预防和治疗中的 15-前列腺素脱氢酶 (15-PGDH)

基本信息

  • 批准号:
    10524057
  • 负责人:
  • 金额:
    $ 93.2万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-12-29 至 2023-11-30
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT Dr. Sanford Markowitz is recognized for making multiple landmark discoveries in the genetics of gastrointestinal (GI) cancers. Markowitz made the seminal discovery that mutations that inactivate TGF-β signaling are a key step in the development of most human GI cancers. Moreover, Markowitz then identified 15- Prostaglandin Dehydrogenase (15-PGDH) as: i) a novel tumor suppressor of GI cancers and ii) a key down stream effector induced by TGF-β. Moreover, Markowitz pioneered inventing molecular tests for early detection of colon and esophagus cancers, based on detecting aberrantly methylated tumor DNA in body excretions. We particularly base this proposal on the Markowitz team's groundbreaking work discovering the role of 15- PGDH in colon cancer. In recent studies published in Science, Science Translational Medicine, and PNAS, our laboratory has rewritten the classical pathway connecting increased PGE2 to colon cancer, discovering: i) 15- PGDH, a prostaglandin degrading enzyme is: a) a potent in vivo antagonist of COX-2, b) a potent colon cancer suppressor gene, and c) turned off in 85% of colon cancers. ii) Further, we have shown 15-PGDH functions as a key negative regulator of proliferation of tissue stem cells after tissue injury. iii) We have identified germline genetic variants of 15-PGDH, and its pathway partner PGT, that are associated with: a) an increased risk of colon cancer plus b) reduced function of 15-PGDH. iv) We have shown in many people colon 15-PGDH levels are reduced by as much as 12-fold. v) We have shown having low colon 15-PGDH confers resistance to the colon tumor prevention effects of COX enzyme inhibitors, celecoxib and aspirin, identifying the first resistance mechanism for these commonly used NSAID drugs. vi) We have developed a totally new class of compounds that can re-induce 15-PGDH in colon cancers, and shown they work via inhibiting a novel and unanticipated pathway mediating 15-PGDH protein degradation. Our vision is that 15-PGDH now provides major new opportunities for identifying individuals at high colon cancer risk, for developing new strategies for colon cancer prevention, and for developing new methods for colon cancer treatment. Goals that we propose to pursue are: i) To identify the fundamental mechanism by which the 15-PGDH pathway regulates stem like cells in the colon. ii) To identify the mechanism by which 15-PGDH level is itself regulated in the colon. iii) To utilize 15-PGDH (plus its partner genes in PGE2 metabolism) to develop powerful new tests to better identify individuals at high colon cancer risk. iv) To similarly utilize 15-PGDH (plus its partner genes in PGE2 metabolism) to develop new and powerful new tests to better identify individuals who are sensitive or resistant to NSAIDs for colon cancer chemoprevention. Furthermore, we propose to develop 15-PGDH as a therapeutic target for colon cancer prevention and for colon cancer treatment, by v) developing new strategies for up-regulating 15-PGDH mRNA expression in the colon, and vi) developing new drugs that stabilize and increase active 15-PGDH protein in the colon, and that are based on a novel compound we have discovered that blocks 15-PGDH protein turnover.
项目总结/摘要 桑福德·马科维茨博士因在遗传学领域的多项里程碑式发现而闻名, 胃肠道(GI)癌症。马科维茨有了开创性的发现, 信号传导是大多数人胃肠道癌症发展的关键步骤。此外,马科维茨随后确定了15- 前列腺素脱氢酶(15-PGDH)作为:i)一种新的胃肠道肿瘤抑制因子和ii)一种关键的下调 TGF-β诱导的流效应子。此外,马科维茨率先发明了用于早期检测的分子测试 结肠癌和食道癌,基于检测身体排泄物中异常甲基化的肿瘤DNA。 我们特别基于Markowitz团队的开创性工作,发现了15- PGDH在结肠癌中的应用在最近发表在《科学》、《科学转化医学》和《PNAS》上的研究中,我们 一个实验室改写了将PGE 2增加与结肠癌联系起来的经典途径,发现:i)15- PGDH,一种前列腺素降解酶,是:a)考克斯-2的有效体内拮抗剂,B)有效结肠癌 抑制基因,以及c)在85%的结肠癌中关闭。ii)此外,我们已经显示15-PGDH功能为 组织损伤后组织干细胞增殖的关键负调节因子。iii)我们已经确定了生殖系 15-PGDH及其途径伴侣PGT的遗传变异,与以下相关:a)增加的 结肠癌加B)15-PGDH功能降低。iv)我们已经在许多人的结肠中显示了15-PGDH水平 减少了12倍v)我们已经显示具有低结肠15-PGDH赋予对结肠癌的抗性。 考克斯酶抑制剂塞来昔布和阿司匹林的结肠肿瘤预防作用,确定第一个耐药 这些常用的NSAID药物的机制。vi)我们开发了一种全新的化合物 它可以在结肠癌中重新诱导15-PGDH,并显示它们通过抑制一种新的和意想不到的 途径介导15-PGDH蛋白降解。我们的愿景是,15-PGDH现在提供主要的新 识别结肠癌高危个体的机会,制定结肠癌新策略 预防和开发结肠癌治疗的新方法。我们建议追求的目标是: i)鉴定15-PGDH途径调节结肠中干细胞样细胞的基本机制。 ii)鉴定结肠中15-PGDH水平自身调节的机制。㈢利用15-PGDH (plus PGE 2代谢中的伴侣基因),以开发强大的新测试,以更好地识别处于高水平的个体。 结肠癌风险。iv)类似地利用15-PGDH(加上其在PGE 2代谢中的伴侣基因)来开发新的 和强大的新测试,以更好地确定谁是敏感或耐药的非甾体抗炎药的结肠癌的个人 化学预防此外,我们建议开发15-PGDH作为结肠癌的治疗靶点 通过v)开发上调15-PGDH mRNA的新策略, vi)开发稳定和增加结肠中活性15-PGDH蛋白的新药, 结肠,并且基于我们发现的阻断15-PGDH蛋白质周转的新型化合物。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury.
  • DOI:
    10.1080/0886022x.2020.1870139
  • 发表时间:
    2021-12
  • 期刊:
  • 影响因子:
    3
  • 作者:
    Kim BW;Kim HJ;Kim SH;Baik HJ;Kang MS;Kim DH;Markowitz SD;Kang SW;Bae KB
  • 通讯作者:
    Bae KB
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SANFORD D. MARKOWITZ其他文献

SANFORD D. MARKOWITZ的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SANFORD D. MARKOWITZ', 18)}}的其他基金

Chemical, Structural and Cell-Signaling Interrogation of 15-Prostanglandin Dehydrogenase in Tissue Repair and Regeneration
15-前列腺素脱氢酶在组织修复和再生中的化学、结构和细胞信号传导研究
  • 批准号:
    10627860
  • 财政年份:
    2021
  • 资助金额:
    $ 93.2万
  • 项目类别:
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment
针对癌症风险、预防和治疗中的 15-前列腺素脱氢酶 (15-PGDH)
  • 批准号:
    9406781
  • 财政年份:
    2016
  • 资助金额:
    $ 93.2万
  • 项目类别:
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment
针对癌症风险、预防和治疗中的 15-前列腺素脱氢酶 (15-PGDH)
  • 批准号:
    10305660
  • 财政年份:
    2016
  • 资助金额:
    $ 93.2万
  • 项目类别:
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment
针对癌症风险、预防和治疗中的 15-前列腺素脱氢酶 (15-PGDH)
  • 批准号:
    9183207
  • 财政年份:
    2016
  • 资助金额:
    $ 93.2万
  • 项目类别:
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment
针对癌症风险、预防和治疗中的 15-前列腺素脱氢酶 (15-PGDH)
  • 批准号:
    10058813
  • 财政年份:
    2016
  • 资助金额:
    $ 93.2万
  • 项目类别:
Role of gene enhancer elements in colon cancer
基因增强子元件在结肠癌中的作用
  • 批准号:
    8449075
  • 财政年份:
    2012
  • 资助金额:
    $ 93.2万
  • 项目类别:
Role of gene enhancer elements in colon cancer
基因增强子元件在结肠癌中的作用
  • 批准号:
    8289140
  • 财政年份:
    2012
  • 资助金额:
    $ 93.2万
  • 项目类别:
Role of gene enhancer elements in colon cancer
基因增强子元件在结肠癌中的作用
  • 批准号:
    8633432
  • 财政年份:
    2012
  • 资助金额:
    $ 93.2万
  • 项目类别:
Case GI SPORE
案例 GI 孢子
  • 批准号:
    8528379
  • 财政年份:
    2011
  • 资助金额:
    $ 93.2万
  • 项目类别:
Targeting 15-PGDH in Colon Cancer Prognosis, Prediction, Treatment and Prevention
以 15-PGDH 为靶点进行结肠癌的预后、预测、治疗和预防
  • 批准号:
    8555227
  • 财政年份:
    2011
  • 资助金额:
    $ 93.2万
  • 项目类别:

相似海外基金

The role of the E3 igase TRIM-25 in the control of caspase-2 translation and its implication for chemotherapy resistance of colon carcinoma cells
E3 igase TRIM-25在控制caspase-2翻译中的作用及其对结肠癌细胞化疗耐药的影响
  • 批准号:
    263162954
  • 财政年份:
    2014
  • 资助金额:
    $ 93.2万
  • 项目类别:
    Research Grants
Clarification of molecular mechanisms of the programmed cell death induced by quercetin derivatives in human colon carcinoma cells.
阐明槲皮素衍生物诱导人结肠癌细胞程序性细胞死亡的分子机制。
  • 批准号:
    26850084
  • 财政年份:
    2014
  • 资助金额:
    $ 93.2万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
COBRE: RIH: THEME A: FETAL PROTEINS & PHENOTYPES IN CANCER: COLON CARCINOMA
COBRE:RIH:主题 A:胎儿蛋白质
  • 批准号:
    7960508
  • 财政年份:
    2009
  • 资助金额:
    $ 93.2万
  • 项目类别:
Transcriptional Regulation and Pathogenetic Relevance of IL-28/IL-29 Cytokine System in Colitis and Colitis Associated Colon Carcinoma (C03)
IL-28/IL-29细胞因子系统在结肠炎和结肠炎相关结肠癌中的转录调控和致病相关性(C03)
  • 批准号:
    84927582
  • 财政年份:
    2008
  • 资助金额:
    $ 93.2万
  • 项目类别:
    CRC/Transregios
Regulation and Function of PTP-PEST in colon carcinoma
PTP-PEST在结肠癌中的调控及功能
  • 批准号:
    8014970
  • 财政年份:
    2007
  • 资助金额:
    $ 93.2万
  • 项目类别:
Regulation and Function of PTP-PEST in colon carcinoma
PTP-PEST在结肠癌中的调控及功能
  • 批准号:
    7414877
  • 财政年份:
    2007
  • 资助金额:
    $ 93.2万
  • 项目类别:
Influence of mismatch repair status on the cytotoxicity and mechanism of action of 5-Fluorouracil in colon carcinoma cells
错配修复状态对5-氟尿嘧啶对结肠癌细胞的细胞毒作用及作用机制的影响
  • 批准号:
    53121559
  • 财政年份:
    2007
  • 资助金额:
    $ 93.2万
  • 项目类别:
    Research Grants
Regulation and Function of PTP-PEST in colon carcinoma
PTP-PEST在结肠癌中的调控及功能
  • 批准号:
    8413256
  • 财政年份:
    2007
  • 资助金额:
    $ 93.2万
  • 项目类别:
Regulation and Function of PTP-PEST in colon carcinoma
PTP-PEST在结肠癌中的调控及功能
  • 批准号:
    7769907
  • 财政年份:
    2007
  • 资助金额:
    $ 93.2万
  • 项目类别:
Regulation and Function of PTP-PEST in colon carcinoma
PTP-PEST在结肠癌中的调控及功能
  • 批准号:
    7571723
  • 财政年份:
    2007
  • 资助金额:
    $ 93.2万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了